Structural insight into G2019S mutated LRRK2 kinase and brain-penetrant type I inhibitor complex: a molecular dynamics approach

References

• Anand, V. S., Reichling, L. J., Lipinski, K., Stochaj, W., Duan, W., Kelleher, K., Pungaliya, P., Brown, E. L., Reinhart, P. H., Somberg, R., Hirst, W. D., Riddle, S. M., & Braithwaite, S. P. (2009). Investigation of leucine-rich repeat kinase 2: Enzymological properties and novel assays. The FEBS Journal, 276(2), 466–478. https://doi.org/10.1111/j.1742-4658.2008.06789.x
   PubMedGoogle Scholar
• Bao, H., Wang, W., Sun, H., & Chen, J. (2023). The switch states of the GDP-bound HRAS affected by point mutations: A study from Gaussian accelerated molecular dynamics simulations and free energy landscapes. Journal of Biomolecular Structure & Dynamics, 0, 1–19. https://doi.org/10.1080/07391102.2023.2213355
   Google Scholar
• Bayly, C. I., Cieplak, P., Cornell, W., & Kollman, P. A. (1993). A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: The RESP model. The Journal of Physical Chemistry, 97(40), 10269–10280. https://doi.org/10.1021/j100142a004
   Web of Science ®Google Scholar
• Berg, D., Schweitzer, K. J., Leitner, P., Zimprich, A., Lichtner, P., Belcredi, P., Brüssel, T., Schulte, C., Maass, S., Nägele, T., Wszolek, Z. K., & Gasser, T. (2005). Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson’s disease*. Brain : A Journal of Neurology, 128(Pt 12), 3000–3011. https://doi.org/10.1093/brain/awh666
   PubMedGoogle Scholar
• Bucher, D., Pierce, L. C. T., McCammon, J. A., & Markwick, P. R. L. (2011). On the use of accelerated molecular dynamics to enhance configurational sampling in ab initio simulations. Journal of Chemical Theory and Computation, 7(4), 890–897. https://doi.org/10.1021/ct100605v
   PubMed Web of Science ®Google Scholar
• Carlsson, A., Lindqvist, M., & Magnusson, T. (1957). 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature, 180(4596), 1200–1200. https://doi.org/10.1038/1801200a0
   PubMed Web of Science ®Google Scholar
• Case, D. A., Babin, V., Berryman, J. T., Betz, R. M., Cai, Q., Cerutti, D. S., Cheatham, T. E., Darden, T. A., Duke, R. E., Gohlke, H., Goetz, A. W., Gusarov, S., Homeyer, N., Janowski, P., Kaus, J., Kolossváry, I., Kovalenko, A., Lee, T. S., LeGrand, S., … Kollman, P. A. (2015). AMBER 14 University of California.
   Google Scholar
• Chan, B. K., Estrada, A. A., Chen, H., Atherall, J., Baker-Glenn, C., Beresford, A., Burdick, D. J., Chambers, M., Dominguez, S. L., Drummond, J., Gill, A., Kleinheinz, T., Le Pichon, C. E., Medhurst, A. D., Liu, X., Moffat, J. G., Nash, K., Scearce-Levie, K., Sheng, Z., … Sweeney, Z. K. (2013). Discovery of a highly selective, brain-penetrant aminopyrazole LRRK2 inhibitor. ACS Medicinal Chemistry Letters, 4(1), 85–90. https://doi.org/10.1021/ml3003007
   PubMed Web of Science ®Google Scholar
• Chen, H., Chan, B. K., Drummond, J., Estrada, A. A., Gunzner-Toste, J., Liu, X., Liu, Y., Moffat, J., Shore, D., Sweeney, Z. K., Tran, T., Wang, S., Zhao, G., Zhu, H., & Burdick, D. J. (2012). Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. Journal of Medicinal Chemistry, 55(11), 5536–5545. https://doi.org/10.1021/jm300452p
   PubMed Web of Science ®Google Scholar
• Chen, J., Zeng, Q., Wang, W., Sun, H., & Hu, G. (2022). Decoding the identification mechanism of an SAM-III Riboswitch on ligands through multiple independent Gaussian-accelerated molecular dynamics simulations. Journal of Chemical Information and Modeling, 62(23), 6118–6132. https://doi.org/10.1021/acs.jcim.2c00961
   PubMedGoogle Scholar
• Choi, H. G., Zhang, J., Deng, X., Hatcher, J. M., Patricelli, M. P., Zhao, Z., Alessi, D. R., & Gray, N. S. (2012). Brain penetrant LRRK2 inhibitor. ACS Medicinal Chemistry Letters, 3(8), 658–662. https://doi.org/10.1021/ml300123a
   PubMed Web of Science ®Google Scholar
• Choi, M., Kim, J. G., Muniyappan, S., Kim, H., Kim, T. W., Lee, Y., Lee, S. J., Kim, S. O., & Ihee, H. (2021). Effect of the abolition of intersubunit salt bridges on allosteric protein structural dynamics. Chemical Science, 12(23), 8207–8217. https://doi.org/10.1039/d1sc01207j
   PubMed Web of Science ®Google Scholar
• Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967). Aromatic amino acids and modification of Parkinsonism. The New England Journal of Medicine, 276(7), 374–379. https://doi.org/10.1056/NEJM196702162760703
   PubMed Web of Science ®Google Scholar
• Covy, J. P., & Giasson, B. I. (2009). Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochemical and Biophysical Research Communications, 378(3), 473–477. https://doi.org/10.1016/j.bbrc.2008.11.048
   PubMed Web of Science ®Google Scholar
• Cox, S., Radzio-Andzelm, E., & Taylor, S. S. (1994). Domain movements in protein kinases. Current Opinion in Structural Biology, 4(6), 893–901. https://doi.org/10.1016/0959-440x(94)90272-0
   PubMed Web of Science ®Google Scholar
• David, C. C., & Jacobs, D. J. (2014). Principal component analysis: A method for determining the essential dynamics of proteins. Methods in Molecular Biology (Clifton, N.J.), 1084, 193–226. https://doi.org/10.1007/978-1-62703-658-0_11
   PubMedGoogle Scholar
• Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J.-D., Patricelli, M. P., Nomanbhoy, T. K., Alessi, D. R., & Gray, N. S. (2011). Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2. Nature Chemical Biology, 7(4), 203–205. https://doi.org/10.1038/nchembio.538
   PubMed Web of Science ®Google Scholar
• Ding, X., Dai, X., Long, K., Peng, C., Andreotti, D., Bamborough, P., Eatherton, A. J., Edge, C., Jandu, K. S., Nichols, P. L., Philps, O. J., Stasi, L. P., Wan, Z., Xiang, J.-N., Dong, K., Dossang, P., Ho, M.-H., Li, Y., Mensah, L., … Ren, F. (2017). Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. Bioorganic & Medicinal Chemistry Letters, 27(17), 4034–4038. https://doi.org/10.1016/j.bmcl.2017.07.052
   PubMed Web of Science ®Google Scholar
• Essmann, U., Perera, L., Berkowitz, M. L., Darden, T., Lee, H., & Pedersen, L. G. (1995). A smooth particle mesh Ewald method. The Journal of Chemical Physics, 103(19), 8577–8593. https://doi.org/10.1063/1.470117
   Web of Science ®Google Scholar
• Estrada, A. A., & Sweeney, Z. K. (2015). Chemical biology of leucine-rich repeat kinase 2 (LRRK2) inhibitors. Journal of Medicinal Chemistry, 58(17), 6733–6746. https://doi.org/10.1021/acs.jmedchem.5b00261
   PubMed Web of Science ®Google Scholar
• Estrada, A. A., Liu, X., Baker-Glenn, C., Beresford, A., Burdick, D. J., Chambers, M., Chan, B. K., Chen, H., Ding, X., DiPasquale, A. G., Dominguez, S. L., Dotson, J., Drummond, J., Flagella, M., Flynn, S., Fuji, R., Gill, A., Gunzner-Toste, J., Harris, S. F., … Sweeney, Z. K. (2012). Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. Journal of Medicinal Chemistry, 55(22), 9416–9433. https://doi.org/10.1021/jm301020q
   PubMed Web of Science ®Google Scholar
• Farrer, M., Stone, J., Mata, I. F., Lincoln, S., Kachergus, J., Hulihan, M., Strain, K. J., & Maraganore, D. M. (2005). LRRK2 mutations in Parkinson disease. Neurology, 65(5), 738–740. https://doi.org/10.1212/01.wnl.0000169023.51764.b0
   PubMed Web of Science ®Google Scholar
• Fell, M. J., Mirescu, C., Basu, K., Cheewatrakoolpong, B., DeMong, D. E., Ellis, J. M., Hyde, L. A., Lin, Y., Markgraf, C. G., Mei, H., Miller, M., Poulet, F. M., Scott, J. D., Smith, M. D., Yin, Z., Zhou, X., Parker, E. M., Kennedy, M. E., & Morrow, J. A. (2015). MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. The Journal of Pharmacology and Experimental Therapeutics, 355(3), 397–409. https://doi.org/10.1124/jpet.115.227587
   PubMed Web of Science ®Google Scholar
• Franzini, M., Ye, X. M., Adler, M., Aubele, D. L., Garofalo, A. W., Gauby, S., Goldbach, E., Probst, G. D., Quinn, K. P., Santiago, P., Sham, H. L., Tam, D., Truong, A., & Ren, Z. (2013). Triazolopyridazine LRRK2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters, 23(7), 1967–1973. https://doi.org/10.1016/j.bmcl.2013.02.043
   PubMed Web of Science ®Google Scholar
• Fuji, R. N., Flagella, M., Baca, M., Baptista, M. A. S., Brodbeck, J., Chan, B. K., Fiske, B. K., Honigberg, L., Jubb, A. M., Katavolos, P., Lee, D. W., Lewin-Koh, S.-C., Lin, T., Liu, X., Liu, S., Lyssikatos, J. P., O'Mahony, J., Reichelt, M., Roose-Girma, M., … Watts, R. J. (2015). Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Science Translational Medicine, 7(273), 273ra15. https://doi.org/10.1126/scitranslmed.aaa3634
   PubMed Web of Science ®Google Scholar
• Gancia, E., Groot, M. D., Burton, B., & Clark, D. E. (2017). Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods. Bioorganic & Medicinal Chemistry Letters, 27(11), 2520–2527. https://doi.org/10.1016/j.bmcl.2017.03.098
   PubMed Web of Science ®Google Scholar
• Gan-Or, Z., Dion, P. A., & Rouleau, G. A. (2015). Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease. Autophagy, 11(9), 1443–1457. https://doi.org/10.1080/15548627.2015.1067364
   PubMed Web of Science ®Google Scholar
• Garofalo, A. W., Adler, M., Aubele, D. L., Brigham, E. F., Chian, D., Franzini, M., Goldbach, E., Kwong, G. T., Motter, R., Probst, G. D., Quinn, K. P., Ruslim, L., Sham, H. L., Tam, D., Tanaka, P., Truong, A. P., Ye, X. M., & Ren, Z. (2013). Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors. Medicinal Chemistry Letters, 23(7), 1974–1977. https://doi.org/10.1016/j.bmcl.2013.02.041
   PubMed Web of Science ®Google Scholar
• Gilsbach, B. K., Ho, F. Y., Vetter, I. R., van Haastert, P. J. M., Wittinghofer, A., & Kortholt, A. (2012). Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations. Proceedings of the National Academy of Sciences of the United States of America, 109(26), 10322–10327. https://doi.org/10.1073/pnas.1203223109
   PubMed Web of Science ®Google Scholar
• Gilsbach, B. K., Messias, A. C., Ito, G., Sattler, M., Alessi, D. R., Wittinghofer, A., & Kortholt, A. (2015). Structural characterization of LRRK2 inhibitors. Journal of Medicinal Chemistry, 58(9), 3751–3756. https://doi.org/10.1021/jm5018779
   PubMed Web of Science ®Google Scholar
• Grant, B. J., Rodrigues, A. P. C., ElSawy, K. M., McCammon, J. A., & Caves, L. S. D. (2006). Bio3d: an R package for the comparative analysis of protein structures. Bioinformatics (Oxford, England), 22(21), 2695–2696. https://doi.org/10.1093/bioinformatics/btl461
   PubMed Web of Science ®Google Scholar
• Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., Ahmad, R., Miller, D. W., Kesavapany, S., Singleton, A., Lees, A., Harvey, R. J., Harvey, K., & Cookson, M. R. (2006). Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiology of Disease, 23(2), 329–341. https://doi.org/10.1016/j.nbd.2006.04.001
   PubMed Web of Science ®Google Scholar
• Hamelberg, D., Mongan, J., & McCammon, J. A. (2004). Accelerated molecular dynamics: A promising and efficient simulation method for biomolecules. The Journal of Chemical Physics, 120(24), 11919–11929. https://doi.org/10.1063/1.1755656
   PubMed Web of Science ®Google Scholar
• Hariharan, P. C., & Pople, J. A. (1973). The influence of polarization functions on molecular orbital hydrogenation energies. Theoretica Chimica Acta, 28(3), 213–222. https://doi.org/10.1007/BF00533485
   Google Scholar
• Hatcher, J. M., Choi, H. G., Alessi, D. R., & Gray, N. S. (2017). Small-molecule inhibitors of LRRK2. Advances in Neurobiology, 14, 241–264.
   PubMedGoogle Scholar
• Hatcher, J. M., Zhang, J., Choi, H. G., Ito, G., Alessi, D. R., & Gray, N. S. (2015). Discovery of a pyrrolopyrimidine (JH-II-127), a highly potent, selective, and brain penetrant LRRK2 inhibitor. ACS Medicinal Chemistry Letters, 6(5), 584–589. https://doi.org/10.1021/acsmedchemlett.5b00064
   PubMed Web of Science ®Google Scholar
• Henderson, J. L., Kormos, B. L., Hayward, M. M., Coffman, K. J., Jasti, J., Kurumbail, R. G., Wager, T. T., Verhoest, P. R., Noell, G. S., Chen, Y., Needle, E., Berger, Z., Steyn, S. J., Houle, C., Hirst, W. D., & Galatsis, P. (2015). Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. Journal of Medicinal Chemistry, 58(1), 419–432. https://doi.org/10.1021/jm5014055
   PubMed Web of Science ®Google Scholar
• Humphrey, W., Dalke, A., & Schulten, K. (1996). VMD—Visual molecular dynamics. Journal of Molecular Graphics, 14(1), 33–38. https://doi.org/10.1016/0263-7855(96)00018-5
   PubMedGoogle Scholar
• Hunter, J. D. (2007). Matplotlib: A 2D graphics environment. Computing in Science & Engineering, 9(3), 90–95. https://doi.org/10.1109/MCSE.2007.55
   Web of Science ®Google Scholar
• Izaguirre, J. A., Catarello, D. P., Wozniak, J. M., & Skeel, R. D. (2001). Langevin stabilization of molecular dynamics. The Journal of Chemical Physics, 114(5), 2090–2098. https://doi.org/10.1063/1.1332996
   Web of Science ®Google Scholar
• Jaleel, M., Nichols, R. J., Deak, M., Campbell, D. G., Gillardon, F., Knebel, A., & Alessi, D. R. (2007). LRRK2 phosphorylates moesin at threonine-558: Characterization of how Parkinson’s disease mutants affect kinase activity. The Biochemical Journal, 405(2), 307–317. https://doi.org/10.1042/BJ20070209
   PubMed Web of Science ®Google Scholar
• Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. The Journal of Chemical Physics, 79(2), 926–935. https://doi.org/10.1063/1.445869
   Web of Science ®Google Scholar
• Kalia, C., V, L., & Lang, A. E. (2015). Parkinson’s disease. Lancet (London, England), 386(9996), 896–912. https://doi.org/10.1016/S0140-6736(14)61393-3
   PubMed Web of Science ®Google Scholar
• Khan, N. L., Jain, S., Lynch, J. M., Pavese, N., Abou-Sleiman, P., Holton, J. L., Healy, D. G., Gilks, W. P., Sweeney, M. G., Ganguly, M., Gibbons, V., Gandhi, S., Vaughan, J., Eunson, L. H., Katzenschlager, R., Gayton, J., Lennox, G., Revesz, T., Nicholl, D., … Wood, N. W. (2005). Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson’s disease: Clinical, pathological, olfactory and functional imaging and genetic data. Brain : A Journal of Neurology, 128(Pt 12), 2786–2796. https://doi.org/10.1093/brain/awh667
   PubMedGoogle Scholar
• Lang, C. A., Ray, S. S., Liu, M., Singh, A. K., & Cuny, G. D. (2015). Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking. Bioorganic & Medicinal Chemistry Letters, 25(13), 2713–2719. https://doi.org/10.1016/j.bmcl.2015.04.027
   PubMed Web of Science ®Google Scholar
• Liu, M., Bender, S. A., Cuny, G. D., Sherman, W., Glicksman, M., & Ray, S. S. (2013). Type II kinase inhibitors show an unexpected inhibition mode against Parkinson’s disease-linked LRRK2 mutant G2019S. Biochemistry, 52(10), 1725–1736. https://doi.org/10.1021/bi3012077
   PubMed Web of Science ®Google Scholar
• Liu, M., Kang, S., Ray, S., Jackson, J., Zaitsev, A. D., Gerber, S. A., Cuny, G. D., & Glicksman, M. A. (2011). Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant. Biochemistry, 50(43), 9399–9408. https://doi.org/10.1021/bi201173d
   PubMed Web of Science ®Google Scholar
• Lu, X., Smaill, J. B., & Ding, K. (2020). New promise and opportunities for allosteric kinase inhibitors. Angewandte Chemie (International ed. in English), 59(33), 13764–13776. https://doi.org/10.1002/anie.201914525
   PubMed Web of Science ®Google Scholar
• Lukman, S., Lane, D. P., & Verma, C. S. (2013). Mapping the structural and dynamical features of multiple p53 DNA binding domains: Insights into loop 1 intrinsic dynamics. PLoS One, 8(11), e80221. https://doi.org/10.1371/journal.pone.0080221
   PubMed Web of Science ®Google Scholar
• Luzón-Toro, B., Rubio de la Torre, E., Delgado, A., Pérez-Tur, J., & Hilfiker, S. (2007). Mechanistic insight into the dominant mode of the Parkinson’s disease-associated G2019S LRRK2 mutation. Human Molecular Genetics, 16(17), 2031–2039. https://doi.org/10.1093/hmg/ddm151
   PubMed Web of Science ®Google Scholar
• Maier, J. A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K. E., & Simmerling, C. (2015). ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. Journal of Chemical Theory and Computation, 11(8), 3696–3713. https://doi.org/10.1021/acs.jctc.5b00255
   PubMed Web of Science ®Google Scholar
• Marín, I. (2006). The Parkinson disease gene LRRK2: Evolutionary and structural insights. Molecular Biology and Evolution, 23(12), 2423–2433. https://doi.org/10.1093/molbev/msl114
   PubMed Web of Science ®Google Scholar
• Miao, Y. L., Nichols, S. E., Gasper, P. M., Metzger, V. T., & McCammon, J. A. (2013). Activation and dynamic network of the M2 muscarinic receptor. Proceedings of the National Academy of Sciences of the United States of America, 110(27), 10982–10987. https://doi.org/10.1073/pnas.1309755110
   PubMed Web of Science ®Google Scholar
• Miller, B. R., Mcgee, T. D., Swails, J. M., Homeyer, N., Gohlke, H., & Roitberg, A. E. (2012). MMPBSA.py: An efficient program for end-state free energy calculations. Journal of Chemical Theory and Computation, 8(9), 3314–3321. https://doi.org/10.1021/ct300418h
   PubMed Web of Science ®Google Scholar
• Mills, R. D., Mulhern, T. D., Liu, F., Culvenor, J. G., & Cheng, H.-C. (2014). Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2). Human Mutation, 35(4), 395–412. https://doi.org/10.1002/humu.22515
   PubMed Web of Science ®Google Scholar
• Myasnikov, A., Zhu, H., Hixson, P., Xie, B., Yu, K., Pitre, A., Peng, J., & Sun, J. (2021). Structural analysis of the full-length human LRRK2. Cell, 184(13), 3519–3527.e10. https://doi.org/10.1016/j.cell.2021.05.004
   PubMed Web of Science ®Google Scholar
• Ni, D., Wei, J., He, X., Rehman, A. U., Li, X., Qiu, Y., Pu, J., Lu, S., & Zhang, J. (2021). Discovery of cryptic allosteric sites using reversed allosteric communication by a combined computational and experimental strategy. Chemical Science, 12(1), 464–476. https://doi.org/10.1039/d0sc05131d
   Web of Science ®Google Scholar
• Paisán-Ruíz, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., López de Munain, A., Aparicio, S., Gil, A. M., Khan, N., Johnson, J., Martinez, J. R., Nicholl, D., Martí Carrera, I., Pena, A. S., de Silva, R., Lees, A., Martí-Massó, J. F., Pérez-Tur, J., Wood, N. W., & Singleton, A. B. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron, 44(4), 595–600. https://doi.org/10.1016/j.neuron.2004.10.023
   PubMed Web of Science ®Google Scholar
• Parkinson's Foundation. n.d. https://www.parkinson.org/Understanding-Parkinsons/statistics, (Accessed April 25, 2023).
   Google Scholar
• Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., & Halliday, G. (2015). Movement Disorders
   Google Scholar
• Ramsden, N., Perrin, J., Ren, Z., Lee, B. D., Zinn, N., Dawson, V. L., Tam, D., Bova, M., Lang, M., Drewes, G., Bantscheff, M., Bard, F., Dawson, T. M., & Hopf, C. (2011). Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson’s disease-related toxicity in human neurons. ACS Chemical Biology, 6(10), 1021–1028. https://doi.org/10.1021/cb2002413
   PubMed Web of Science ®Google Scholar
• Reith, A. D., Bamborough, P., Jandu, K., Andreotti, D., Mensah, L., Dossang, P., Choi, H. G., Deng, X., Zhang, J., Alessi, D. R., & Gray, N. S. (2012). GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorganic & Medicinal Chemistry Letters, 22(17), 5625–5629. https://doi.org/10.1016/j.bmcl.2012.06.104
   PubMed Web of Science ®Google Scholar
• Ring, S., Taymans, J.-M., Baekelandt, V., & Schmidt, B. (2014). Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond. Bioorganic & Medicinal Chemistry Letters, 24(19), 4630–4637. https://doi.org/10.1016/j.bmcl.2014.08.049
   PubMed Web of Science ®Google Scholar
• Ryckaert, J.-P., Ciccotti, G., & Berendsen, H. J. C. (1977). Numerical integration of the cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. Journal of Computational Physics, 23(3), 327–341. https://doi.org/10.1016/0021-9991(77)90098-5
   Web of Science ®Google Scholar
• Salomon-Ferrer, R., Case, D. A., & Walker, R. C. (2013). Wiley Interdiscip. Wiley Interdisciplinary Reviews: Computational Molecular Science, 3(2), 198–210. https://doi.org/10.1002/wcms.1121
   Web of Science ®Google Scholar
• Scott, D. W. (1992). John Wiley & Sons, New York, Chicester
   Google Scholar
• Scott, J. D., Demong, D. E., Greshock, T. J., Basu, K., Dai, X., Harris, J., Hruza, A., Li, S. W., Lin, S.-I., Liu, H., Macala, M. K., Hu, Z., Mei, H., Zhang, H., Walsh, P., Poirier, M., Shi, Z.-C., Xiao, L., Agnihotri, G., … Miller, M. W. (2017). Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) Inhibitor that reduces brain kinase activity. Journal of Medicinal Chemistry, 3, 2983–2992.
   Google Scholar
• Sharp, K. A., & Honig, B. (1990). Calculating total electrostatic energies with the nonlinear Poisson-Boltzmann equation. The Journal of Physical Chemistry, 94(19), 7684–7692. https://doi.org/10.1021/j100382a068
   Web of Science ®Google Scholar
• Smith, G. P., Badolo, L., Chell, V., Chen, I.-J., Christensen, K. V., David, L., Daechsel, J. A., Hentzer, M., Herzig, M. C., Mikkelsen, G. K., Watson, S. P., & Williamson, D. S. (2017). The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors. Bioorganic & Medicinal Chemistry Letters, 27(18), 4500–4505. https://doi.org/10.1016/j.bmcl.2017.07.072
   PubMed Web of Science ®Google Scholar
• Tan, S., Zhang, Q., Wang, J., Gao, P., Xie, G., Liu, H., & Yao, X. (2022). Molecular modeling study on the interaction mechanism between the LRRK2 G2019S mutant and type I inhibitors by integrating molecular dynamics simulation, binding free energy calculations, and pharmacophore modeling. ACS Chemical Neuroscience, 13(5), 599–612. https://doi.org/10.1021/acschemneuro.1c00726
   PubMed Web of Science ®Google Scholar
• Taylor, S. S., & Kornev, A. P. (2011). Protein kinases: Evolution of dynamic regulatory proteins. Trends in Biochemical Sciences, 36(2), 65–77. https://doi.org/10.1016/j.tibs.2010.09.006
   PubMed Web of Science ®Google Scholar
• Taymans, J.-M., & Greggio, E. (2016). LRRK2 kinase inhibition as a therapeutic strategy for Parkinson’s Disease, Where do we stand? Current Neuropharmacology, 14(3), 214–225. https://doi.org/10.2174/1570159x13666151030102847
   PubMed Web of Science ®Google Scholar
• Tsika, E., & Moore, D. J. (2013). Contribution of GTPase activity to LRRK2-associated Parkinson disease. Small GTPases, 4(3), 164–170. https://doi.org/10.4161/sgtp.25130
   PubMedGoogle Scholar
• Ufimtsev, I. S., & Martínez, T. J. (2009a). Quantum chemistry on graphical processing units. 1. Strategies for two-electron integral evaluation. Journal of Chemical Theory and Computation, 5, 1004–1015.
   PubMed Web of Science ®Google Scholar
• Ufimtsev, I. S., & Martínez, T. J. (2009b). Quantum chemistry on graphical processing units. 2. Direct self-consistent-field implementation. Journal of Chemical Theory and Computatio,. 2009, 5, 1004–1015.
   PubMed Web of Science ®Google Scholar
• Ufimtsev, I. S., & Martínez, T. J. (2009). Quantum chemistry on graphical processing units. 3. Analytical energy gradients, geometry optimization, and first principles molecular dynamics. Journal of Chemical Theory and Computation, 5, 2619–2628 https://doi.org/10.1021/ct800526s
   PubMed Web of Science ®Google Scholar
• Wang, E., Sun, H., Wang, J., Wang, Z., Liu, H., Zhang, J. Z. H., & Hou, T. (2019). End-point binding free energy calculation with MM/PBSA and MM/GBSA: Strategies and applications in drug design. Chemical Reviews, 119(16), 9478–9508. https://doi.org/10.1021/acs.chemrev.9b00055
   PubMed Web of Science ®Google Scholar
• Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general amber force field. Journal of Computational Chemistry, 25(9), 1157–1174. https://doi.org/10.1002/jcc.20035
   PubMed Web of Science ®Google Scholar
• Weng, J.-H., Ma, W., Wu, J., Sharma, P. K., Silletti, S., McCammon, J. A., & Taylor, S. (2023). Capturing differences in the regulation of LRRK2 dynamics and conformational states by small molecule kinase inhibitors. ACS Chemical Biology, 18(4), 810–821. https://doi.org/10.1021/acschembio.2c00868
   PubMed Web of Science ®Google Scholar
• West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005). Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences of the United States of America, 102(46), 16842–16847. https://doi.org/10.1073/pnas.0507360102
   PubMed Web of Science ®Google Scholar
• Williamson, D. S., Smith, G. P., Acheson-Dossang, P., Bedford, S. T., Chell, V., Chen, I.-J., Daechsel, J. C. A., Daniels, Z., David, L., Dokurno, P., Hentzer, M., Herzig, M. C., Hubbard, R. E., Moore, J. D., Murray, J. B., Newland, S., Ray, S. C., Shaw, T., Surgenor, A. E., … Christensen, K. V. (2017). Design of leucine-rich repeat kinase 2 (LRRK2) inhibitors using a crystallographic surrogate derived from checkpoint kinase 1 (CHK1). Journal of Medicinal Chemistry, 60(21), 8945–8962. https://doi.org/10.1021/acs.jmedchem.7b01186
   PubMed Web of Science ®Google Scholar
• Williamson, D. S., Smith, G. P., Mikkelsen, G. K., Jensen, T., Acheson-Dossang, P., Badolo, L., Bedford, S. T., Chell, V., Chen, I.-J., Dokurno, P., Hentzer, M., Newland, S., Ray, S. C., Shaw, T., Surgenor, A. E., Terry, L., Wang, Y., & Christensen, K. V. (2021). Design and synthesis of pyrrolo[2,3-d]pyrimidine-derived leucine-rich repeat kinase 2 (LRRK2) inhibitors using a checkpoint kinase 1 (CHK1)-derived crystallographic surrogate. Journal of Medicinal Chemistry, 64(14), 10312–10332. https://doi.org/10.1021/acs.jmedchem.1c00720
   PubMed Web of Science ®Google Scholar
• Zhang, J., Deng, X., Choi, H. G., Alessi, D. R., & Gray, N. S. (2012). Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorganic & Medicinal Chemistry Letters, 22(5), 1864–1869. https://doi.org/10.1016/j.bmcl.2012.01.084
   PubMed Web of Science ®Google Scholar
• Zhu, H., Chen, H., Cho, W., Estrada, A. A., & Sweeney, Z. K. (2013). Wiley-VCH Verlag GmbH & Co. KGaA.
   Google Scholar
• Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., Stoessl, A. J., Pfeiffer, R. F., Patenge, N., Carbajal, I. C., Vieregge, P., Asmus, F., Müller-Myhsok, B., Dickson, D. W., Meitinger, T., … Gasser, T. (2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44(4), 601–607. https://doi.org/10.1016/j.neuron.2004.11.005
   PubMed Web of Science ®Google Scholar